Bullish Moving Averages
0
Bearish Moving Averages
9
Back Stocks profile
Open Price
35.40Prev. Close
36.4000Volume
294361.00Value
10332071.10Market Cap Cr
1053.00
Price to Earnings
15.00
Price to Book Value
2.60
Dividend Yield
0.00
PE to Growth
0.00
Op Revenue TTM Cr
1379.78
Net Profit TTM Cr
69.98
Cash From Operating Activity Cr
-150.41
Return on Equity %
17.68
EMA & SMA
Bullish Moving Averages
0
Bearish Moving Averages
9
DELIVERY AND VOLUME
18 May, 2024
Week
Month
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
PIVOT
First Resistance
35.37
Second Resistance
35.63
Third Resistance
35.87
First Support
34.87
Second Support
34.63
Third Support
34.37
Relative Strength Index
39.92
Money Flow Index
44.49
MACD
-0.57
MACD Signal
-0.52
Average True Range
1.2
Average Directional Index
10.81
Rate of Change (21)
-3.04
Rate of Change (125)
Commodity Channel Index
-80.3
Williams %R
-84.2
BETA
1 Month
0.54
3 Month
1 Year
3 Year
PRICE CHANGE ANALYSIS
1 Week
Low
High
34.65
38.3
1 Month
Low
High
34.5
38.3
3 Months
Low
High
33
43.95
6 Months
Low
High
33
43.95
1 Year
Low
High
33
43.95
Mukka Proteins Ltd - 544135 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Plese find enclosed herewith copies of Newspaper Advertisements confirming completion of dispatch of Postal Ballot Notice to the shareholders.Mukka Proteins Ltd - 544135 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
We are enclosing herewith the Postal Ballot Notice dated 14th May 2024 along with explanatory statement.Mukka Proteins Ltd - 544135 - Newspaper Advertisement Pursuant To Regulation 47 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
We are hereby enclosing copies of Newspaper Advertisement of Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended 31st March 2024.Q4FY24 Quarterly & FY24 Annual Result Announced for Mukka Proteins Ltd.
Food Products company Mukka Proteins announced Q4FY24 & FY24 results: PAT for Q4 FY24, increased by 141.53% to Rs 29.15 crore from 12.07 crore in Q3FY24 (QoQ comparison) and increased by 32.99% in Q4FY24 from Rs 21.92 crore in Q4FY23 (YoY comparison) For the entire FY24, PAT increased by 56.35% to Rs 74.31 crore, from Rs 47.52 crore in FY23 On a QoQ basis, the EBITDA margins increased by 177.47%, to 14.38% in Q4FY24 from 5.18% in Q3FY24, indicating 920 bps improvement in the margins EBIDTA has improved by 37.77% to Rs 36.92 crore in Q4FY24 from Rs 26.80 crore in Q3FY24 PAT % as a % of Revenue has improved by 386.44%, to 11.36% in Q4FY24 from 2.33% in Q3FY24 and has improved by 117.96% compared to Q4FY23. On this occasion, Mohammed Haris, MD and CEO, Mukka Proteins said "We are extremely proud of the strong operational performance of the company in Q4FY24. The improvement in the margins clearly indicates that the management is focused on improving the profitability going forward as well. The use of IPO proceeds in the working capital requirements has boarded extremely well with the plans visualized by the management of the company. The sector promises to witness strong growth momentum going further in FY25 and in recent times the support from the Government through various schemes like Pradhan Mantri Matsya Sampada Yojana (PMMSY), Fisheries and Aquaculture Infrastructure Development Fund, Blue revolution 2.0 will only boost the prospects of the industry going forward. Our aim will be to surpass the industry growth and ensure that all our stakeholders including investors are extremely happy with the company’s performance”. Result PDFMukka Proteins Ltd - 544135 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
We are enclosing herewith the Monitoring Agency Report dated May 14, 2024, issued by ICRA Limited for the quarter ended March 31, 2024.Mukka Proteins Ltd - 544135 - Statement Of Deviation(S) Or Variation(S) Of Funds Raised Through Initial Public Offer (''IPO'') For The Quarter Ended March 31, 2024
Please find enclosed herewith the statement of deviation(s) or variation(s) in utilization of funds raised through IPO for the quarter ended March 31, 2024.Mukka Proteins Ltd - 544135 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Intimation of Press ReleaseMukka Proteins Ltd - 544135 - Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended 31St March 2024.
Audited financial results for the quarter and year ended 31st March 2024.Mukka Proteins Ltd - 544135 - Audited Financial Results For The Quarter And Year Ended 31St March 2024.
Audited financial results for the quarter and year ended 31st March 2024.Mukka Proteins Ltd - 544135 - Board Meeting Intimation for Intimation Of Board Meeting.
Mukka Proteins Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2024 ,inter alia, to consider and approve We wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, 14th May 2024, inter alia to consider and approve the audited financial results (standalone and consolidated) of the Company for the quarter and year ended 31st March 2024.The latest market price of Mukka Proteins Ltd. on NSE was Rs. 35.10 as of today.
The opening share price of Mukka Proteins Ltd. was Rs. 35.40 as of today.
The 52-week high share price of Mukka Proteins Ltd. was Rs. 44.00.
The 52 week low share price of Mukka Proteins Ltd. was Rs. 33.00.
Mukka Proteins Ltd. has a market cap of Rs. 1053.00 crore as of today. Please refer to the Fundamentals section for further details.
The PE ratio of Mukka Proteins Ltd. is 0.00. Please refer to the Fundamentals section for further details.
The operating revenue for Mukka Proteins Ltd. in the last FY was Rs. 1379.78 crore. Please refer to the Financials section for further details.
The Net Profit for Mukka Proteins Ltd. in the last FY was Rs. 69.98 crore. Please refer to the Financials section for further details.
Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.
Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.
Please refer to Bigul Traders Corner, One Stop destination for different algo and non-algo trading strategies and tools meant for investors, traders, and strategists. Our qualified experts with rich experience in broking, financial analysis, and software development designed it in-house. Click here to learn more.
Please refer to JARVIS, which is Bigul’s AI Portfolio Manager Tool that uses artificial intelligence algorithms to make investment decisions in a portfolio. Click here to learn more.
Please refer to the News section for the latest news about Mukka Proteins Ltd..